Systemic Lupus Erythematosus Market is expected to register growth at a CAGR of 6.0% over the forecast period
The global systemic lupus erythematosus market size is expected to register growth at a CAGR of 6.0% over the forecast period of 2021-2030.
Lupus, also known as systemic lupus erythematosus (SLE),
is a chronic inflammatory disease that causes tissue inflammation throughout
the body. Fatigue, fever, skin rashes, joint discomfort, malaise, and brief
loss of cognitive ability are all prominent signs of the condition. Individuals
may experience different signs and symptoms.
Download
Request for Sample@ https://bit.ly/3Q48vIy
The kidneys, skin, joints, lungs, central nervous system,
and blood-forming (hematopoietic) system are all affected by the condition,
which affects connective tissues that provide strength and flexibility to
bodily structures and many organs and systems. Although the primary aetiology
of the condition is unknown, a complicated genetic and hormonal basis has been
discovered in a few investigations. The severity of the disease varies from
mild to severe, and it is more common in women, affecting people between the
ages of 25 and 45. A form of lupus is said to affect at least 5.0 million
people worldwide. The disease's therapies in development focus on a wide range
of targets.
GROWTH DRIVERS:
With 30 trials completed, GlaxoSmithKline is presently
the company with the most completed clinical trials for SLE, followed by
AstraZeneca. Benlysta (2011), a medication developed by GlaxoSmithKline, is the
only medicine approved for SLE in the last 50 years. The number of medicines in
development for moderate to severe SLE without active renal disease and/or
lupus nephritis is also rising, indicating that the market will continue to
increase in the coming years.
Additionally, biologics for autoimmune disorders are
gaining more physician approval and confidence as they significantly improve
disease treatment. In addition, some of the main pipeline biologics that are
now through phase III clinical trials are projected to hit the market in the
next few years, fueling the market because these medications could provide more
effective alternatives to the lupus nephritis patient population. Benlysta is
also in high demand, particularly in developed nations. All of these variables are
projected to have a substantial impact on market growth in the future years.
SYSTEMIC LUPUS
ERYTHEMATOSUS MARKET SEGMENTATION:
By Drug Classes:
· NSAID
· Corticosteroids
· Antimalarials
· Immunosuppressants
· Biologics
By Route of
Administration:
· Oral
· Intravenous
· Subcutaneous
· Topical
By Distribution
Channel:
· Retail
Pharmacies
· Hospitals
· Online
Pharmacies
By Region:
· North
America
· Europe
· Asia
Pacific
· Latin
America
· Middle
East and Africa
Immunosuppressants had the greatest share of the market
in 2020, based on medication classifications. Due to factors such as the
increased worldwide usage of methotrexate and other immunosuppressants due to
their low cost and great accessibility, the sector is likely to continue to
lead the market throughout the projection period. During the forecast period of
2021-2030, however, the biologics category is expected to increase at the
fastest rate of 13.0 percent.
In terms of route of administration, the oral segment
dominated the market in 2020, accounting for 54.0 percent of the market,
followed by the intravenous sector. Over the forecast term, the tendency is expected
to continue.
In 2020, the hospitals segment accounted for the biggest
proportion of the market, followed by the retail pharmacies segment. During the
projected period of 2021-2030, the categories are expected to maintain their
market dominance.
KEY COMPANIES IN
SYSTEMIC LUPUS ERYTHEMATOSUS MARKET:
· Pfizer
· Novartis
· Bayer
· Amgen
Inc.
· Bristol-Myers
Squibb Company
· GlaxoSmithKline
PLC
· Immunomedics
Inc.
· Johnson
& Johnson
· MedImmune
LLC
· Merck
Serono GmbH
· Sanofi
SA
· Teva
Pharmaceutical Industries Ltd.
· UCB
SA
· F.
Hoffmann-La Roche Ltd.
· Hansa
Medical Ab
· Harbor
Biosciences
· Other
Players
Read
More Information: https://www.xresearch.biz/shop/systemic-lupus-erythematosus-market
About
Us:-
xResearch is a market
research and consulting organization that uses unique data, expert analysis,
and new technologies to create trusted intelligence on industries. Our research
is focused on delivering an informed and impartial view on essential market
data of industry, and it is primarily driven by an in-depth study covering the
following parameters: Market Sizing and Forecasting, Market Segmentation, Competitive Analysis, Strategic Assessment and Business Modelling.
Contact:
Company Name: xResearch
Contact Person: James Lin
Email: sales@xresearch.biz
Phone: +1 718-618-4545

Comments
Post a Comment